An Overview of COVID-19 Vaccine Safety and Post-marketing Surveillance Systems

  • Manal Mohammed Younus Iraqi Pharmacovigilance Center, Ministry of Health, Iraq
  • Ali Azeez Al-Jumaili University of Baghdad College of Pharmacy, Baghdad, Iraq


The need for the safety monitoring of the COVID-19 vaccine is unprecedented. It is an ongoing process starting from different phases of clinical trials and continued to post-marketing to tackle the emergency used authorized COVID-19 vaccines across the world. Rapid detection, exchange, prioritization, and assessment of safety signals based on available real-world data, surveillance of Adverse events following immunization (AEFI), and adverse event of special interest (AESI) by studying the observed/expected cases. Enhanced collaboration, and availability of resources, tools, and methods will add to the lessons learned from previous experiences.


Download data is not yet available.
Received 2021-08-01
Published 2021-10-12
Pharmacy Practice & Practice-Based Research